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When all conventional treatments for respiratory failure in patients with acute respiratory distress syndrome
(ARDS) have failed, extracorporeal membrane oxygenation (ECMO) can provide a chance of survival in these
desperately ill patients. A 49-year-old male patient developed septic shock and progressive ARDS after liver
abscess drainage. Venovenous ECMO was given due to refractory respiratory failure on postoperative day 6.
Initially, two heparin-binding hollow-fiber microporous membrane oxygenators in parallel were used in the
ECMO circuit. Twenty-two oxygenators were changed in the first 22 days of ECMO support because of plasma
leak in the oxygenators. Each oxygenator had an average life of 48 hours. Thereafter, a single silicone membrane
oxygenator was used in the ECMO circuit, which did not require change during the remaining 596 hours of
ECMO. The patient’s tidal volume was only 90 mL in the nadir and less than 300 mL for 26 days during the
ECMO course. The patient required ECMO support for 48 days and survived despite complications, including
septic shock, ARDS, acute renal failure, drug-induced leukopenia, and multiple internal bleeding. This patient
received an unusually long duration of ECMO support. However, he survived, recovered well, and was in
New York Heart Association functional class I–II, with a forced expiratory volume in 1 second of 81% of the
predicted level 18 months later. In conclusion, ECMO can provide a chance of survival for patients with
refractory ARDS. The reversibility of lung function is possible in ARDS patients regardless of the severity of
lung dysfunction at the time of treatment. [J Formos Med Assoc 2006;105(5):422–426]
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There are many different treatments for acute
respiratory distress syndrome (ARDS), including
prone positioning, nitric oxide inhalation, sur-
factant therapy, high frequency oscillatory venti-
lation, and partial liquid ventilation. However,
extracorporeal membrane oxygenation (ECMO)
is always the last hope for ARDS patients who
are unresponsive to all other treatments. We re-
port a patient with liver abscess complicated by
septic shock and ARDS, who received ECMO
support for 48 days during a complicated post-
operative course.
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Case Report
A 49-year-old, 80-kg man had fever, chills, and
upper abdominal pain for 4 days. He visited a lo-
cal hospital for help. Hematology examination
revealed a white blood cell count of 610/μL and
platelet count of 53 × 103/μL. Abdominal sono-
graphy found a liver abscess measuring 7.4 × 7
cm. Under the impression of liver abscess with
sepsis, he was transferred to our hospital. Vital
signs on admission were: body temperature of
37.7°C, blood pressure of 99/58 mmHg, and
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to the patient through a 21-Fr cannula in the right
internal jugular vein.
Under ECMO support, a lung-protection venti-
lator strategy (PEEP 15 cmH2O, PIP ) 35 cmH2O,
and the lowest FiO2 to keep SpO2 * 90%) was
adopted to prevent ventilator-induced lung in-
jury. Initial ECMO blood flow was 2.7 L/min and
sweep gas flow was 10 L/min. Heparin infusion
was used to keep activated clotting time (ACT)
around 160 seconds. However, PaO2 was only
50.3 mmHg under ventilator FiO2 at 1.0, and lung
function continued to deteriorate (Figure). Be-
cause of unsatisfactory PaO2 on the second day
of ECMO support (POD 7), another 25-Fr venous
cannula was inserted into the inferior vena cava
through the left femoral vein, and ECMO blood
flow was increased to 3.7 L/min. PaO2 increased
from 45.7 mmHg to 64.0 mmHg thereafter, and
ventilator FiO2 was gradually decreased to 0.7
within 4 days.
Because most blood was drained through the
larger 25-Fr cannula in the left femoral vein, the
other smaller drainage cannula in the right femo-
ral vein was occluded after thrombus formation
was found on POD 8. However, ECMO blood
flow remained almost unchanged after removal
of the occluded right femoral venous cannula and
change of the whole ECMO circuit. On POD 9 and
POD 10, the oxygenator was changed due to plas-
ma leak. The plasma leak and short working dura-
tion of the oxygenators was attributed to a high
heart rate of 130/min. Ceftriaxone and metroni-
dazole were given and dopamine was infused for
hypotension, and the patient was sent to the in-
tensive care unit (ICU) for further care. Seven hours
later, the patient was intubated because of hy-
poxemia (SpO2, 90%) and tachypnea (45/min).
Because of rapid progressive septic shock, emer-
gency surgical drainage of the liver abscess was
arranged 14 hours after admission; 50 mL of pus
was drained from an abscess at segments 7 and
8 of the liver, and several rubber drains were left
in place for further drainage.
The patient’s condition progressively deterio-
rated after the operation. Infusion of dopamine and
norepinephrine was required for septic shock, and
the ventilator setting was increased for ARDS.
Bacterial culture of liver pus and blood both re-
vealed Klebsiella pneumoniae. Despite the sensiti-
vity of the isolate to the ceftriaxone that was ini-
tially administered, the patient’s clinical condition
continued to deteriorate. Prone positioning and
nitric oxide inhalation were tried, but without re-
sponse. On postoperative day (POD) 6, tube tho-
racostomy was performed due to left pneumo-
thorax. Under the ventilator setting of pressure-
controlled mode, positive end-expiratory pressure
(PEEP) was 21.5 cmH2O, peak inspiratory pressure
(PIP) was 38.9 cmH2O, mean airway pressure
(MAP) was 29.5 cmH2O, and oxygen fraction
(FiO2) was 1.0; arterial blood gas analysis showed
a pH of 7.211, PaCO2 of 92.4 mmHg, PaO2 of
34.0 mmHg, HCO3
–1 of 35.5 mmol/L, and lactate
of 4.2 mmol/L.
Because of poor lung function (oxygenation
index, 87; AaDO2 563 and compliance 26.5 mL/
cmH2O) and unstable hemodynamics, venove-
nous ECMO (VV-ECMO) was set up to support the
patient. The ECMO system was composed of a
centrifugal pump and a microporous membrane
oxygenator with an integrated heater (CB2505;
Medtronic Inc, Minneapolis, MN, USA). The en-
tire ECMO system had a heparin-binding surface.
Venous blood was drained from the right femoral
vein through a 23-Fr venous cannula, and passed
through the centrifugal pump. Gas exchange was
performed in the oxygenator, followed by return
Figure. Inspired oxygen fraction (FiO2) required for mechanical ventilation
and patient’s lung compliance during intensive care unit stay.
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blood flow used in our VV-ECMO setting. To avoid
recurrence of this problem, another oxygenator
was added in parallel to the previous oxygenator
in the ECMO circuit. This increased total ECMO
blood flow from 3.7 L/min to 4.3 L/min, but each
oxygenator had a lower blood flow (2.1 L/min and
2.2 L/min). However, in the subsequent ECMO
course, oxygenator plasma leak continued to oc-
cur. From POD 11 to POD 28, 19 oxygenators were
changed due to plasma leak. On average, each oxy-
genator worked properly for 48 hours. On POD
28, a single silicone membrane oxygenator (I-
4500-2A; Medtronic Inc), which had not previously
been available, was used to replace the two hol-
low-fiber microporous membrane oxygenators in
parallel in the ECMO circuit. Because this silicone
membrane oxygenator has no heparin-binding
surface, ACT was kept at a higher level of 180
seconds. Oxygenator plasma leak did not occur
thereafter during 597 hours of silicone membrane
oxygenator use until ECMO was weaned off on
POD 53.
The entire course of VV-ECMO support was 48
days. Under the lung-protection ventilator strate-
gy (PIP ) 35 cmH2O, PEEP ) 15 cmH2O), tidal
volume was only 90 mL on POD 9 and tidal vol-
ume ) 300 mL was maintained for 26 days from
POD 9 to POD 34. Ventilator FiO2 could be kept
) 0.6 throughout most of the ECMO course to
prevent complications from oxygen toxicity.
Although ECMO support saved the life of this
patient, its prolonged course resulted in many
complications. Acinetobacter baumanii was found
in the sputum culture, and meropenem was pre-
scribed on POD 13. However, leukopenia devel-
oped 10 days later with a white blood cell nadir
of 440/μL and neutrophils of 260/μL. The com-
plication was treated with daily granulocyte
colony-stimulating factor 300 mg intramuscular
injection for 7 days. The patient recovered well
without sequelae.
One episode of non-oliguric renal failure oc-
curred because of hypovolemic shock due to se-
vere plasma leak from the oxygenator, and hemo-
dialysis was performed twice to treat this com-
plication.
On POD 35, prone positioning was tried to
improve oxygenation status. However, right
inguinal hematoma was noted the next day. On
POD 40, intramuscular hematomas were noted
in the right thigh, left arm and forearm, which
were attributed to bleeding tendency from pro-
longed ECMO. Bilateral hemothorax was also
noted, and blood oozed along the left chest
tube with a daily loss of around 500 mL. During
the last 15 days of ECMO support (POD 38 to
POD 52), 58 units of packed red blood cells
were transfused to the patient. Another oliguric
acute renal failure developed without obvious
etiology. Hemodialysis was performed daily
from POD 47 to POD 63, and renal function
finally recovered also.
On POD 53, the patient was successfully
weaned from ECMO after 48 days. Immediately
afterward, heparin infusion was stopped, and plate-
let transfusion and tranexamic acid injection were
given to control bleeding. Right tube thoracosto-
my and left open chest window were performed
for bilateral hemothorax. Tracheotomy was also
performed to facilitate the following respiratory
care. Thereafter, the patient gradually recovered.
He was weaned off the ventilator on POD 76,
discharged from the ICU on POD 83, and dis-
charged from the hospital on POD 155. Eighteen
months after the operation, the patient was in
New York Heart Association functional class I–
II, and pulmonary function tests showed a
forced vital capacity (FVC) of 2.79 L (81.8% of
predicted), forced expiratory volume in 1 second
(FEV1) of 2.32 L (81% of predicted), diffusing
capacity for carbon monoxide (DLCO) of 10.4 L
(43.2% of predicted) and DLCO/alveolar volume
of 2.54.
Discussion
The International Summary of Extracorporeal
Life Support Registry reported in January 2005
that 136 patients had received ECMO for post-
operative/trauma ARDS. The average duration of
ECMO treatment was 240 hours, and the survi-
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val rate was 51%.1 However, due to severe ARDS,
pneumothorax with persistent air leak, and sever-
al postoperative complications, our patient re-
quired ECMO support for 48 days.
The patient did not respond to prone position-
ing and nitric oxide inhalation. Liquid ventilation
was not feasible at the time of treatment. Whether
high frequency oscillatory ventilation could have
stabilized the patient remains unclear, especially
in the presence of hemodynamic instability. In
comparison, ECMO immediately provided ade-
quate cardiopulmonary support and allowed a
lower ventilator setting (PIP ) 35 cmH2O, FiO2 )
0.6) to prevent further ventilator-induced lung
injury. The lowest tidal volume was only 90 mL,
and a tidal volume ) 300 mL was maintained for
26 days during the ECMO course. Thus, ECMO
support saved the life of this patient and allowed
good lung recovery later. At 18 months after the
event, FVC and FEV1 were nearly normal, although
DLCO was moderately impaired. Herridge et al re-
ported that average FEV1 in ARDS survivors was
83% of normal at 1 year after the event.2 Reversi-
bility of lung function may be expected in ARDS
survivors, regardless of the severity of lung dys-
function during the episode.
Multiple organ failure is the most common
etiology of mortality in modern ICUs. This patient
had complications of septic shock, acute renal
failure, ARDS, drug-induced leukopenia, and mul-
tiple internal bleeding. In addition to convention-
al intensive care, including antibiotic adminis-
tration, adequate tissue perfusion, and enteral
feeding, advanced artificial organ support of pro-
longed ECMO support and aggressive daily he-
modialysis were needed to help this patient sur-
vive a complicated postoperative course.
The initial oxygenators used in ECMO were
heparin-binding microporous membrane oxy-
genators. They had several advantages over sili-
cone membrane oxygenators, including less
priming volume, excellent gas transfer capability,
and ease of priming. Moreover, a heparin-binding
surface results in less blood activation and cytokine
release,3,4 and reduces systemic heparinization
requirement. This is an especially important ad-
vantage for postoperative patients with a higher
risk of bleeding. However, plasma leak is a com-
mon problem of microporous membrane oxy-
genators. A smaller membrane pore size can de-
lay the occurrence of plasma leak, but cannot pre-
vent it.5 A total of 22 microporous oxygenators
were used during the course of ECMO in this pa-
tient. Frequent oxygenator change was a heavy
burden on the medical personnel who cared for
this patient. In comparison to microporous mem-
brane oxygenators, silicone membrane oxygenators
have disadvantages of a longer time required for
priming, higher priming volume, and more anti-
coagulation requirement; however, they avoid the
complication of plasma leak and have a longer
duration of use. In this patient, the average life of
the microporous membrane oxygenators was 48
hours, but the silicone membrane oxygenator was
still functioning adequately at 579 hours when
weaning from ECMO was completed. Because a
higher ACT was required due to the use of a sili-
cone membrane oxygenator, bleeding was more
of a problem. Gentle nursing care to prevent bleed-
ing is highly emphasized in ECMO care.
In general, when ECMO is used for mechanical
circulatory support in patients with postcardioto-
my cardiogenic shock6 or acute myocarditis,7 the
required duration is usually less than 1 week. De-
cisions regarding the reversibility of underlying
heart disease and suitability of further aggressive
treatment for a specific cardiac patient requiring
ECMO support can usually be made within 48
hours.8 However, ARDS patients always take
longer (up to several weeks) to recover. ARDS is
usually a manifestation of multiple organ fail-
ure, as opposed to lung disease alone. Reliable
criteria to predict the reversibility of ARDS are still
lacking. Unpredicted prolonged ECMO support is
often required in ARDS patients, and the quality
of intensive care received during the prolonged
course is a key factor to successful ECMO treat-
ment for ARDS.
In conclusion, ECMO can provide respiratory
support to ARDS patients for long periods up to
several weeks, thereby providing a chance of sur-
vival to some desperately ill ARDS patients.
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